Peabody John W, Cruz Jamielyn D C, Ganesan Divya, Paculdo David, Critchley-Thorne Rebecca J, Wani Sachin, Shaheen Nicholas J
QURE Healthcare, San Francisco, California, USA.
University of California, San Francisco, California, USA.
Clin Transl Gastroenterol. 2024 Jan 1;15(1):e00644. doi: 10.14309/ctg.0000000000000644.
Barrett's esophagus (BE) is a precursor to esophageal adenocarcinoma. Physicians infrequently adhere to guidelines for managing BE, leading to either reduced detection of dysplasia or inappropriate re-evaluation.
We conducted a three-arm randomized controlled trial with 2 intervention arms to determine the impact of a tissue systems pathology (TSP-9) test on the adherence to evidence-based guidelines for simulated patients with BE. Intervention 1 received TSP-9 results, and intervention 2 had the option to order TSP-9 results. We collected data from 259 practicing gastroenterologists and gastrointestinal surgeons who evaluated and made management decisions for 3 types of simulated patients with BE: nondysplastic BE, indefinite for dysplasia, and low-grade dysplasia.
Intervention 1 was significantly more likely to correctly assess risk of progression to high-grade dysplasia/esophageal adenocarcinoma and offer treatment in accordance with US society guidelines compared with the control group (+6.9%, 95% confidence interval +1.4% to +12.3%). There was no significant difference in ordering guideline-recommended endoscopic eradication therapy. However, for cases requiring annual endoscopic surveillance, we found significant improvement in adherence for intervention 1, with a difference-in-difference of +18.5% ( P = 0.019). Intervention 2 ordered the TSP-9 test in 21.9% of their cases. Those who ordered the test performed similarly to intervention 1; those who did not, performed similarly to the control group.
The TSP-9 test optimized adherence to clinical guidelines for surveillance and treatment of both patients with BE at high and low risk of disease progression. Use of the TSP-9 test can enable physicians to make risk-aligned management decisions, leading to improved patient health outcomes.
巴雷特食管(BE)是食管腺癌的癌前病变。医生很少遵循BE的管理指南,导致发育异常的检测减少或重新评估不当。
我们进行了一项三臂随机对照试验,其中两个干预组,以确定组织系统病理学(TSP-9)检测对模拟BE患者遵循循证指南的影响。干预1组接收TSP-9检测结果,干预2组可选择订购TSP-9检测结果。我们收集了259名执业胃肠病学家和胃肠外科医生的数据,他们对3种模拟BE患者进行了评估并做出管理决策:无发育异常的BE、发育异常不明确和低级别发育异常。
与对照组相比,干预1组更有可能正确评估进展为高级别发育异常/食管腺癌的风险,并根据美国社会指南提供治疗(+6.9%,95%置信区间+1.4%至+12.3%)。在订购指南推荐的内镜根除治疗方面没有显著差异。然而,对于需要每年进行内镜监测的病例,我们发现干预1组的依从性有显著改善,差异为+18.5%(P=0.019)。干预2组在21.9%的病例中订购了TSP-9检测。订购检测的人与干预1组表现相似;未订购检测的人与对照组表现相似。
TSP-9检测优化了对疾病进展风险高和低的BE患者进行监测和治疗的临床指南的依从性。使用TSP-9检测可以使医生做出符合风险的管理决策,从而改善患者的健康结局。